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The receptor tyrosine kinase Met consists of two disulphide-linked
polypeptide chains, a and b, with molecular masses of 50 and
145 kDa respectively (Giordano et al, 1989). Hepatocyte growth
factor (HGF), also known as scatter factor (SF), has been demon-
strated to be the ligand for Met (Bottaro et al, 1991; Naldini et al,
1991). Met is expressed in a variety of cell types, mainly of epithe-
lial origin (Zarnegar and Michalopoulos, 1995). Activation results
in a number of cellular responses, such as growth, motility and
morphogenesis, depending on cell type (Stoker et al, 1987;
Higashio et al, 1990; Rubin et al, 1991; Weidner et al, 1991). In the
cytoplasmic domain of the receptor protein there are two tyrosine
phosphorylation sites (Y1234 and Y1235) needed for activation of
the kinase domain (Longati et al, 1994; Zhen et al, 1994), and two
others for association with different SH2-domain containing
signalling proteins (Y1349 and Y1356) (Ponzetto et al, 1994). Met
has been shown to interact with Grb2, phospholipase C-g (PLC-g),
phosphoinositol (PI) 3-kinase, Shc and Src (Bardelli et al, 1992,
1994), as well as Gab 1 (Weidner et al, 1996) and a tyrosine phos-
phatase (SHP2/Syp 2) (Villa-Moruzzi et al, 1993; Fixman et al,
1996). Recently, it was demonstrated that a member of the ets
family of transcription factors, ets 1, positively regulates the
expression of Met (Gambarotta et al, 1996).
Overexpression of Met has been reported in several different
types of carcinomas, including ovarian (Di Renzo et al, 1994),
pancreatic (Di Renzo et al, 1995a), colorectal (Di Renzo et al,
1991; Prat et al, 1991) and thyroid carcinomas (Di Renzo et al,
1991, 1992, 1995b). High expression of Met protein was found in
approximately 70% of papillary thyroid carcinomas. The overex-
pression was not related to gene amplification, but the histotype of
the tumours correlated to bad prognosis for the patients (Di Renzo
et al, 1992). In normal thyroid epithelium in vivo Met is only
expressed at a very low level (Di Renzo et al, 1991, 1992).
However, HGF has been shown to be a very potent mitogen for
both human and dog thyroid follicle cells (Dremier et al, 1994;
Eccles et al, 1996). Besides the growth stimulatory effect,
HGF also induced de-differentiation of the thyrocytes, as have
been observed after stimulation with other thyroid mitogens
(Westermark et al, 1983). Furthermore, expression of HGF has
also been found within the human thyroid (Zarnegar et al, 1990),
making a paracrine stimulation possible in the regulation of
thyroid follicle cell growth and function.
In the present study we have investigated the expression and
activity of Met in human anaplastic thyroid carcinoma cell lines,
as well as in non-neoplastic human thyrocytes in primary culture.
We found an overexpression of Met in a majority of the carcinoma
cell lines, viz. in HTh 83, C 643, SW 1736 and KAT-4, compared
to the level found in normal thyrocytes. In these thyroid carci-
nomas, Met appeared to be constitutively activated in a ligand-
independent fashion.
MATERIALS AND METHODS
Cell lines
The human anaplastic thyroid carcinoma cell lines HTh 7
(Carlsson et al, 1983), HTh 74 (Heldin et al, 1991), HTh 83
(Dahlman et al, unpublished results), C 643 (Heldin et al, 1988),
SW 1736 and KAT-4 (Ain and Taylor, 1994) were routinely grown
in Eagle’s minimal essential medium (HTh 7, HTh 74, C 643 and
SW 1736) or in RPMI 1640 medium (HTh 83 and KAT-4). As a
control for Met expression we used a hepatic carcinoma cell line,
Hep G2, cultured in RPMI 1640 medium. The B-cell line U2889,
used as a control in the Southern blot analysis, was cultured in
RPMI 1640 medium. JJN 3 (Börset et al, 1996), a myeloma cell
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line used as positive control in the HGF Northern blot analysis,
was also cultured in RPMI 1640 medium. All media were supple-
mented with 10% calf serum and antibiotics (100 U of penicillin
and 50 mg of streptomycin per ml). The primary cultures of human
thyroid follicle cells were established by collagenase treatment of
non-neoplastic thyroid tissue (Heldin and Westermark, 1988), and
cultured in F12 medium containing 1% calf serum and antibiotics.
Northern blot analysis
Total RNA was extracted from cells using a LiCl/urea method
(Auffray and Rougeon, 1980), and mRNA was enriched by poly-A+
selection. Total or poly-A+ RNA (15 or 10 mg per lane respectively)
was size-fractionated in a 0.8% agarose gel under denaturating
conditions and transferred to a nitrocellulose filter. The filters were
hybridized as described before (Heldin and Westermark, 1988),
using a 32P-labelled (Megaprime kit; Amersham Pharmacia
Biotech, Uppsala, Sweden) human Met (Rong et al, 1992) or a
0.7 kb human HGF-b subunit cDNA fragment (pKK233-DEb5;
Nakamura et al, 1989). The hybridization with the HGF probe was
performed using QuikHyb solution (Stratagene, La Jolla, CA,
USA). After a wash in 2 ´ saline sodium citrate (SSC) (1 ´ SSC
consists of 0.15 M sodium chloride and 0.125 M sodium citrate, pH
7.0) and 0.5% sodium dodecyl sulphate (SDS) for 30 min at 37°C,
and a subsequent wash in 0.1 ´ SSC and 0.1% SDS at 60°C for 25
min. Filters were autoradiographed at – 70°C using Kodak XAR-5
films and intensifying screens. In order to check for loading differ-
ences the filters were hybridized with a glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH; pGAP) probe (Tso et al, 1985).
Southern blot analysis
Chromosomal DNA was extracted from the cell lines was incu-
bated with proteinase K (100 mg ml–1) in 10 mM Tris–HCl, 1 mM
EDTA, 1% SDS and 0.1 M sodium chloride (NaCl) for 20 h at
37°C, followed by a phenol extraction. Chromosomal DNA was
precipitated in ethanol after extraction twice with isobutanol/
isopropanol (7:3). Chromosomal DNA was digested for 16 h at
37°C with EcoRI and samples were electrophoresed and trans-
ferred to a nitrocellulose filter using standard methods. The filter
was hybridized and autoradiographed as described above (Heldin
and Westermark, 1988). As a control for equal loading, the filter
was stripped and rehybridized with a 3 kb human PAI-1 c DNA
fragment (pPAI3; obtained from Dr Sawdey, Scripps Research
Institute, CA, USA).
Western blot analysis
Cells were incubated with or without HGF (rhHGF; R&D
Systems, Oxford, UK), 10 ng ml–1, for 6 min at 37°C, washed with
phosphate-buffered saline (PBS) containing 1 mM Na3VO4, and
lysed in a buffer consisting of 1% Triton X-100, 150 mM NaCl,
10 mM Tris–HCl pH 7.4, 1 mM EGTA, 1 mM EDTA and 0.5%
NP-40, with protease and phosphatase inhibitors (35 ng ml–1
phenylmethylsulphonyl fluoride (PMSF), 1.4 mg ml–1 aprotinin,
1m M Na3VO4, 10 mM NaF, 1 mM ZnCl2 and 50 mM Na2MoO4).
After a 30 min incubation on ice the lysates were centrifuged
for 15 min at 20 000 g at 4°C. The clear supernatants were
collected and used in the experiments. The protein concentrations
were determined using a commercial kit (Pierce Chemical
Co., Rockford, IL, USA). Following SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing or non-reducing
conditions, an immunoblot analysis was performed using anti-
Met (C-28) or anti-Syp 2 antibodies (C-18, Santa Cruz
Biotechnologies, Santa Cruz, CA, USA), with a secondary horse-
radish peroxidase conjugated anti-rabbit-IgG (Amersham
Pharmacia Biotech, Uppsala, Sweden). Detection of signals was
done with a commercial kit for chemoluminescense (Pierce
Chemical Co., Rockford, IL, USA).
Glycoproteinase F digestion
Total cell lysate (20 mg per sample) from each cell line was diluted
to 100 ml with a buffer consisting of 0.25 M Na2HPO4, pH 7.5,
10 mM EDTA, 10 mM b-mercaptoethanol (b-ME) and 0.5% (w/v)
n-octylglucoside, boiled 3 min and digested with 2 U glycopro-
teinase F (USB, Cleveland, OH, USA) for 24 h at 37°C. Samples
were analysed in a Western blot using the anti-Met antibody.
Immunoprecipitation of tyrosine phosphorylated
proteins
Cell lysates were prepared as described above. Tyrosine phos-
phorylated proteins were immunoprecipitated from 0.5 to 1 mg of
total lysate (0.5 mg for the experiment in Figure 4 and 1.0 mg
for experiment in Figure 5) using agarose-conjugated anti-
phosphotyrosine (PY) antibodies (PY-20-agarose; Transduction
Laboratories, Lexington, KY, USA). Lysates were incubated for
1.5 h at 4°C, and subsequently washed four times in lysis buffer.
The samples were boiled in sample buffer containing b-ME, and
separated on a 7.5% polyacrylamide gel. Immunoblots with the
anti-Met antibody were done as previously described.
Co-immunoprecipitation of Met and Shc proteins
Total cell lysates (1.2 mg per sample) were incubated with anti-Shc
antibodies (1 mg ml–1; PG-797 from Santa Cruz Biotechnologies,
Santa Cruz, CA, USA) for 1 h at 4°C. After another 45 min incuba-
tion with GammaBind Plus Sepharose (Amersham Pharmacia
c-met
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Figure 1 Expression of c-met mRNA in human anaplastic thyroid
carcinoma cell lines. Ten micrograms of poly A+ -RNA were separated in a
0.8% agarose gel, transferred to a nitrocellulose filter and hybridized with a
human Met cDNA probe as described in Materials and Methods652 JD Bergström et al
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Biotech, Uppsala, Sweden) the precipitates were washed three
times in lysis buffer, boiled in SDS-PAGE sample buffer with b-
ME, and Western blots were performed as described above using
the anti-Met antibody.
RT-PCR and sequencing
Total RNA was extracted from the HTh 83 and KAT-4 cells as
described above. The RNA was converted into cDNA using the
forward polymerase chain reaction (PCR) primer as template,
utilizing a commercial kit (GeneAmp, Perkin-Elmer, NJ, USA).
The cDNA was amplified by PCR, 30 cycles, using two primers
spanning exon 18 and 19 of the MET gene: GGCAA-
GAAAATTCACTGTGC (forward) and TCCCAGAGGAC-
GACGCCAAA (reverse). Following PCR, the reaction products
were purified using a commercial kit (Qiaquick PCR-purification
kit, Qiagen, Hilden, Germany) and ligated into the pGEM-T
cloning vector (Promega, Madison, WI, USA). The Met fragments
were sequenced on an ABI 377 automated sequencer, using the
forward and reverse primers described above as sequencing
primers.
RESULTS
Expression of Met in human anaplastic thyroid
carcinoma cell lines
Northern blot analysis of poly-A+-RNA extracted from the
anaplastic thyroid carcinoma cells revealed c-met transcripts in all
six cell lines (Figure 1). The size of the mRNA found was approx-
imately 7 kb, i.e. of the same size as in AG1518 human foreskin
fibroblasts and in the hepatic carcinoma cell line Hep G2. The
amount of Met mRNA observed differed between cell lines;
however, there was a fairly good correlation between the mRNA
level and the amount of Met protein detected in immunoblotting
experiments (Figure 2A); showing a high or very high expression
of Met in HTh 83, C 643, SW 1736 and KAT-4 cell lines,
compared to the Met protein level in primary cultures of non-
neoplastic human thyroid follicle cells (Figure 2B).
The size of the Met protein varied in the different cell lines. This
appeared to be due to differences in glycosylation since treatment
with glycoproteinase F resulted in deglycosylated Met proteins of
similar size (Figure 3).
The high expression of Met observed was not a result of gene
amplification since Southern blot analysis of DNA extracted from
the cell lines did not show any signs of increased MET gene copy
number (Figure 4). As a DNA loading control the filter was
hybridized with a plasminogen activator inhibitor-1 (PAI-1) cDNA
probe with similar results (data not shown).
Constitutive tyrosine phosphorylation of Met
The expressed Met proteins seemed functionally active since stim-
ulation with HGF induced tyrosine phosphorylation of the recep-
tors, determined by immunoprecipitation with anti-PY antibodies
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Figure 2 Met protein level in anaplastic thyroid carcinoma cell lines and
primary cultures of non-neoplastic human thyroid follicle cells. (A) Total cell
lysates (10 mg per lane) from the thyroid carcinoma cell lines were separated
by SDS-PAGE and transferred to a nitrocellulose filter and immunoblotted as
described in Materials and Methods using an anti-Met antibody. To detect the
specificity of the bands observed, the antibody was blocked with the
immunizing peptide prior to the immunoblotting (the lower part of panel A).
(B) Total lysates from primary cultures of non-neoplastic human thyrocytes
were immunoblotted as described above with the anti-Met antibody. In order
to detect Met in total lysates from the primary cultures a prolonged exposure
had to be performed. The amount loaded of Hep G2 lysate was the same in
panels A and B
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Figure 3 Glycoproteinase F digestion of Met in the thyroid carcinoma cell
lines. To study the size differences of Met, 20 mg of total lysate from each cell
line was treated with glycoproteinase F for 24 h to trim off sugar residues.
Untreated and glycoproteinase F treated lysates (3 mg per sample) were
separated by SDS-PAGE and the filter was immunoblotted with the anti-Met
antibodyConstitutive activation of Met in thyroid carcinoma cells 653
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(Figure 5). However, in four of the cell lines, HTh 83, C 643, SW
1736 and KAT-4 cells, we found phosphorylated Met also in
unstimulated cells. This finding suggests a constitutive
phosphorylation and maybe also activation of Met. As seen in
Figure 5, in KAT-4 cells there was virtually no difference between
the amounts of phosphorylated Met precipitated in unstimulated
compared to the HGF-stimulated cells.
To study if the observed tyrosine phosphorylation of Met was
due to endogenous production and autocrine stimulation by HGF,
the HGF expression in the cell lines was investigated. Northern blot
analysis of total RNA extracted from the cell lines showed expres-
sion of HGF mRNA only in the HTh 74 cells, and not in the cell
lines with constitutively phosphorylated Met proteins (Figure 6).
Furthermore, incubation of cells with suramin (200 mg ml–1) for 4
h prior to lysis showed the receptors to be tyrosine phosphorylated
even in the presence of suramin (Figure 7; only results from HTh
83 and KAT-4 are shown, however, similar results were obtained
with the C 643 and SW 1736 cells). Since suramin blocked Met
activation by 10 ng ml–1 of HGF added to the Hep G2 cells (Figure
7), the current findings suggest a ligand-independent phosphoryla-
tion of the receptor in the carcinomas.
Changes or differences in the phosphatase activity might
contribute to the constitutive activation of Met found. Therefore,
we performed Western blot analysis of the phosphatase function-
ally coupled to Met, Syp 2, and also compared the phosphatase
activity in the different cell lines. Syp 2 protein was found in equal
amounts in all cell lines, and we could not detect any differences in
the phosphatase activity (data not shown). Moreover, PCR-ampli-
fication and nucleotide sequencing of exon 17–19 of the kinase
domain of the MET gene, known to contain mutations in renal
carcinomas (Jeffers et al, 1997; Schmidt et al, 1997), did not show
any nucleotide alterations in HTh 83 and KAT-4 cells (data not
shown). To investigate the possibility of covalent dimerization of
receptors due to aberrant di-sulphide bond formation between
cysteine residues in Met, we performed Western blot analysis
under non-reducing conditions of immunoprecipitated Met.
Covalent dimerization would result in a Met species of approxi-
mately 380 kDa; however, this was not detected in HTh 83 or
KAT-4 (data not shown).
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Figure 4 Southern blot analysis of DNA from the anaplastic thyroid
carcinoma cell lines. Chromosomal DNA extracted from the cell lines were
subjected to a Eco R1 digestion for 16 h at 37°C (10 mg per sample).
Southern blot analysis was performed as described in Materials and
Methods, using a 32P-radiolabelled human MET cDNA fragment as probe. As
normal control we used a human EBV-immortalized B-cell line (U2889)
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Figure 5 Immunoprecipitation of Met with a phosphotyrosine antibody
(PY-20). Total cell lysates of unstimulated and HGF-stimulated (10 ng ml–1,
6 min at 37°C) cells were immunoprecipitated with an anti-PY mAb (PY-20)
as described in Materials and Methods. The precipitates were separated
on an SDS-PAGE gel and immunoblotted with the anti-Met antibody
1
5
1
8
H
T
h
 
7
H
T
h
 
7
4
H
T
h
 
8
3
C
 
6
4
3
S
W
 
1
7
3
6
K
A
T
-
4
T
o
x
i
c
 
g
o
i
t
e
r
J
J
N
 
3
– 28 S
– 18 S
HGF
GAPDH
–+–+
––++
–+–+
––++
–+–+
––++
HGF:
Suramin:
Met
IP: a-PY
WB: a-Met
Hep G2 HTh 83 KAT-4
Figure 6 Expression of HGF mRNA in human anaplastic thyroid carcinoma
cell lines. Total RNA (15 mg per lane) was size-fractionated under denaturing
conditions by electrophoresis. Following transfer, the filter was hybridized
with a human HGF cDNA probe as described in Materials and Methods. The
human myeloma cell line JJN 3, known to produce HGF (Börset et al, 1996),
was used as a positive control
Figure 7 Effect of suramin on the constitutive activation of Met in thyroid
carcinoma cells. Hep G2, HTh 83 and KAT-4 cells were incubated 4 h with
suramin (200 mg ml–1), and finally incubated with or without HGF (10 ng ml–1)
for another 6 min. The cells were lysed and total lysates were
immunoprecipitated with anti-PY mAb (PY-20), separated on SDS-PAGE and
immunoblotted using the anti-Met antibody654 JD Bergström et al
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Co-immunoprecipitation of Met and Shc proteins
To demonstrate a functional coupling to intracellular signalling
proteins of the constitutively phosphorylated receptors, we
performed co-immunoprecipitation experiments with anti-Shc
antibodies. As seen in Figure 8, binding of Met to Shc was
detected in lysates from both unstimulated and HGF stimulated
cells in the HTh 83 and KAT-4 cells. However, in the control cells
Hep G2, co-precipitated Met was only seen after HGF stimulation
(Figure 8). Furthermore, we could also precipitate Met in unstimu-
lated KAT-4 cells using GST-fusion proteins with SH2-domains
from PLC-g and Grb2 (data not shown). Thus, it seems as if the
constitutively phosphorylated receptors in the carcinoma cells are
functionally active in signal transduction.
DISCUSSION
Overexpression of Met has been observed in many different kinds
of tumours, and there appears to be a link between Met activation,
neoplastic transformation and malignant behaviour of tumour cells
(Rong et al, 1992, 1994; Scotlandi et al, 1996). Anaplastic (undif-
ferentiated) thyroid carcinoma of the giant cell type is one of the
most aggressive and malignant tumours found in humans. The
tumour usually kills the patient within a year from diagnosis
(Carcangiu et al, 1985). In vivo, normal thyroid tissue barely
expresses Met protein but many thyroid carcinomas have a 100-
fold increase in Met expression (Di Renzo et al, 1991, 1992,
1995b). Interestingly, none of the anaplastic thyroid carcinomas
studied (n = 5) by Di Renzo et al (1995b) had an elevated Met
expression, although, in the same study three out of four poorly
differentiated thyroid carcinomas overexpressed Met. However, in
the present study we found Met expression in all human anaplastic
thyroid carcinoma cell lines studied. Interestingly, in four out of
six cell lines the receptors were found to be tyrosine phosphoryl-
ated even in unstimulated cells, suggesting a constitutive activa-
tion of the receptors. This notion was strengthened by the finding
of an association of Met to the adaptor protein Shc in unstimulated
cells, indicating a functionally active receptor. Thus, our current
data clearly show that some anaplastic thyroid carcinomas have
the capacity to overexpress a constitutively activated Met protein.
Since it is known from other cell types that growth in vitro up-
regulates Met expression (de Juan et al, 1994), we compared the
expression level in the anaplastic thyroid carcinoma cells to the
level found in primary cultures of normal human thyroid follicle
cells. The expression of Met was severalfold higher in some of the
thyroid carcinoma cell lines, compared to control cultures of
normal thyrocytes, clearly showing an overexpression of Met.
Constitutive activation of Met, as observed in the present study,
has previously been reported from a gastric carcinoma cell line
(GTL-16) (Ponzetto et al, 1991), and also in murine melanoma
cells (B16-LS9) (Rusciano et al, 1996). GTL-16 cells overexpress
Met as a result of MET gene amplification (Ponzetto et al, 1991).
So far, the exact mechanism behind the constitutive activation of
Met in the GTL-16 cells has not been revealed; however, it is
neither the result of rearrangements nor mutations of the MET
gene (Ponzetto et al, 1991). A consistent finding in the present and
previous studies is that a ligand-independent activation of Met is
only observed in cell lines where Met is overexpressed (Ponzetto
et al, 1991). Thus, it is possible that an overexpression leads to
constitutive activation of the receptor proteins. Rusciano et al
(1996) suggested that the ligand-independent activation observed
in the B16-LS9 cells may be caused by the high number of recep-
tors present on the cell surface, leading to spontaneous dimeriza-
tion and phosphorylation. However, Ferracini et al (1995) reported
very high expression of Met in the osteosarcoma cell line, U-2 OS,
without any constitutive phosphorylation of the receptor.
Activation of the proto-oncogenes ras and ret is a common
finding in thyroid carcinomas. Recently, Ivan et al (1997) demon-
strated that infection of human thyrocytes with retroviruses
containing activated ras or ret genes led to an up-regulation of the
Met protein level. However, only one of the carcinoma cell lines in
the present study, C 643, had activating ras mutations (Gly13Arg,
in Ha-ras and Ala59Thr in Ki-ras; Ekwall et al, unpublished
results) and none expressed activated ret (Alemi et al, unpublished
results), suggesting that activation of ras or ret is not involved in
the constitutive activation of Met.
Upon nucleotide sequencing of the Met kinase domain we were
unable to detect any mutations in KAT-4 and HTh 83, showing that
mutational activation of Met seems not to be present in our cell
lines. Mutations in the kinase domain of Met in hereditary and
sporadic papillary renal carcinomas were recently reported by
Schmidt et al (1997). The mutations were located in the same
region as activating mutations found in the Ret and Kit tyrosine
kinase receptors, and were suggested to activate Met. The acti-
vating effect of the mutations was later demonstrated by Jeffers et
al (1997). Neither did the HTh 83 or KAT-4 cell lines express a
covalently dimerized receptor species, as judged by Western blot
analysis under non-reducing conditions. This is the case in some of
the mutated forms of Ret, where mutations in the cysteine-rich part
of the extracellular domain yields a covalent association of recep-
tors due to formation of di-sulphide bonds (Santoro et al, 1995).
Receptor phosphorylation and activation could be the result of
an autocrine stimulation by HGF. Simultaneous expression of
HGF and Met has been found in lung carcinoma cells (Tsao et al,
1993), in osteosarcoma cell lines (Ferracini et al, 1995), myeloma
cell lines (Börset et al, 1996) and human breast carcinomas (Tuck
et al, 1996). In the thyroid carcinoma cell lines in the present study
we also found HGF mRNA expression in one of the cell lines
(HTh 74). However, in this cell line we have so far been unable to
demonstrate the existence of an autocrine activation of Met. The
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Figure 8 Co-immunoprecipitation of Shc and Met in HTh 83 and KAT-4
cell lines. Total cell lysates were incubated with anti-Shc antibodies and
GammaBind Plus Sepharose as described in Materials and Methods. After
the immunoprecipitation and repeated washes the samples were boiled and
electrophoresed under reducing conditions, followed by an immunoblot with
the anti-Met antibodycell lines showing constitutive activation of Met did not express
HGF mRNA. Moreover, autocrine activation of Met in the thyroid
carcinoma cells does not seem likely since preincubation with
suramin, which blocks the interaction between HGF and Met
(Adams et al, 1991; Figure 6), had no effect on the phosphoryla-
tion pattern of the receptors, thus further strengthening the conclu-
sion that ligand independent activation of the receptor occurred.
Differences in phosphatase activity, maybe of the protein phos-
phatase functionally coupled to Met (Villa-Moruzzi et al, 1993;
Fixman et al, 1996), could result in an increased fraction of phos-
phorylated Met receptors. Increased phosphatase activity upon
detachment of cells from the substratum leading to a decreased
Met phosphorylation has been observed in murine melanoma cells
(Rusciano et al, 1996). The cell lines in our study express equal
amounts of the phosphatase Syp 2, and so far we have not been
able to detect any differences in the activity of the cellular phos-
phatases. Thus, the constitutive activity of Met is not likely to be
the result of impaired activity of the cellular phosphatases.
The role of the constitutive activation and overexpression of
Met observed in the anaplastic thyroid carcinoma cells is not
known. So far we have been unable to detect any differences
between cells with and without constitutive Met activation with
respect to growth characteristics or migration (data not shown).
However, we speculate that constitutive activation of Met might
have been of importance in early steps of malignant transforma-
tion, but at present stage, the contribution to the malignant pheno-
type is limited due to additional transformational events that these
highly malignant tumour cells have undergone.
In summary, Met is expressed in all human anaplastic thyroid
carcinoma cell lines studied. In four carcinomas with high expres-
sion levels of Met there was a ligand-independent activation of the
receptors. The mechanism(s) behind the constitutive receptor
phosphorylation and activation is not clear; however, receptor
number seems to be an important factor. The importance of the
overexpression and constitutive activation of Met for the malig-
nant phenotype of the anaplastic thyroid carcinoma cells remains
to be elucidated.
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